CIT Inc Bevétel Y / Y
Mi az CIT Inc Bevétel Y / Y?
A Bevétel Y / Y az CIT Group Inc - 80.26%
Mi a Bevétel Y / Y meghatározása?
Az elmúlt 3 évben az éves bevételnövekedés a bevételek növekedése az elmúlt 3 év átlagában az elmúlt 3 évben.
The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.
Bevétel Y / Y a Finance szektor a NYSE-on cégekben a CIT Inc -hoz képest
Mit csinál CIT Inc?
CIT is a leading national bank focused on empowering businesses and personal savers with the financial agility to navigate their goals. CIT Group Inc. (NYSE: CIT) is a financial holding company with over a century of experience and operates a principal bank subsidiary, CIT Bank, N.A. (Member FDIC, Equal Housing Lender). CIT's commercial banking segment includes commercial financing, community association banking, middle market banking, equipment and vendor financing, factoring, railcar financing, treasury and payments services, and capital markets and asset management. CIT's consumer banking segment includes a national direct bank and regional branch network.
bevétel y / y -hoz hasonló cégek CIT Inc
- China Resources Medical nak Bevétel Y / Y 79.83% van
- Kabra Extrusiontechnik nak Bevétel Y / Y 79.97% van
- Agile Therapeutics Inc nak Bevétel Y / Y 79.99% van
- MBH PLC nak Bevétel Y / Y 80.07% van
- CIT nak Bevétel Y / Y 80.14% van
- Matrix Composites & Engineering Ltd nak Bevétel Y / Y 80.17% van
- CIT Inc nak Bevétel Y / Y 80.26% van
- BCI Minerals nak Bevétel Y / Y 80.52% van
- Sprague Resources LP nak Bevétel Y / Y 80.55% van
- UroGen Pharma nak Bevétel Y / Y 80.61% van
- Solar Industries India nak Bevétel Y / Y 80.88% van
- CytomX Therapeutics Inc nak Bevétel Y / Y 80.93% van
- Capital Product Partners L P nak Bevétel Y / Y 81.04% van